UK markets close in 11 minutes
  • FTSE 100

    7,023.89
    +75.90 (+1.09%)
     
  • FTSE 250

    22,172.66
    +5.52 (+0.02%)
     
  • AIM

    1,232.28
    -3.38 (-0.27%)
     
  • GBP/EUR

    1.1676
    +0.0039 (+0.33%)
     
  • GBP/USD

    1.4105
    -0.0039 (-0.28%)
     
  • BTC-GBP

    39,585.49
    -300.62 (-0.75%)
     
  • CMC Crypto 200

    1,512.93
    -50.91 (-3.26%)
     
  • S&P 500

    4,108.98
    -43.12 (-1.04%)
     
  • DOW

    33,996.02
    -273.14 (-0.80%)
     
  • CRUDE OIL

    66.45
    +1.17 (+1.79%)
     
  • GOLD FUTURES

    1,823.90
    -12.20 (-0.66%)
     
  • NIKKEI 225

    28,147.51
    -461.08 (-1.61%)
     
  • HANG SENG

    28,231.04
    +217.23 (+0.78%)
     
  • DAX

    15,193.90
    +74.15 (+0.49%)
     
  • CAC 40

    6,293.22
    +25.83 (+0.41%)
     

Outlook on the Neurotrophic Keratitis Global Market to 2029 - Key Drivers, Challenges and Opportunities

Research and Markets
·6-min read

Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Neurotrophic Keratitis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2021 to 2029. Neurotrophic keratitis is an orphan disease which is primarily caused due to the damage of the fifth cranial nerve from the trigeminal nucleus to the nerve endings preset in the eye corneal region. Traditional therapies are employed to suppress the clinical manifestation occurring in different stages of the disease. Currently RGN-259 developed by ReGenTree, LLC. is in the phase III clinical trial study for the treatment of neurotrophic keratitis.

Recent EMA approval of Oxervate and priority review designation approved by the USFDA will popularize the recombinant human nerve growth factor during the forecast period

Neurotrophic keratitis is a rare degenerative disease which results I loss of corneal sensation and dampens its healing process. The global prevalence rate of neurotrophic keratitis is reported to be 5 per 10,000 individuals. The treatment options adopted for neurotrophic keratitis depends upon the severity and stage of the disease. Artificial tears are prescribed for all the stages due to its ability to provide wetness and lubrication to the corneal surface and ensure cleanliness. Topical antibiotics are majorly prescribed during the stage 2 of the disease for prophylactic treatment of infection. Despite pharmacological treatment and in stage 3 of the disease surgical interventions such as Tarsorraphy and amniotic membrane transplantation is employed to heal corneal ulceration. The recent approval of Oxervate by EMA and priority review designation approved by the USFDA will popularize the utilization of recombinant human nerve growth factor for the treatment of neurotrophic keratitis during the forecast period.

Rising prevalence of neurotrophic keratitis and affordable reimbursement scenario drive the market growth in North America

North America is presently responsible for 33% market share and is leading the regional segment for neurotrophic keratitis market. According to American Academy of Ophthalmology (AAO), approximately 65,000 people in the United States are suffering with this rare disease. The chief contributing factors accountable for its dominance in regional market are rising prevalence of neurotrophic keratitis and affordable reimbursement scenario pertaining to the medication used for its treatment. Europe trails North America in regional market with a share of 28.5% primarily due to strategic collaboration between government healthcare agencies and academic research institutes for the development of novel drugs for treating neurotrophic keratitis in Europe. The European Medical Agency (EMA) has designated orphan disease status to neurotrophic keratitis and has designated fast track status for its drug development and sale in the region. Asia Pacific holds 16% market share owing to the increasing incidence rate of neurotrophic keratitis in geriatric population and supportive regulatory scenario provided by regional healthcare agencies.

Historical & Forecast Period

This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2021 to 2029.

Pharmaceutical companies specializing in providing medication for the treatment of neurotrophic keratitis are Allergan, Plc., Abbott Laboratories, Inc., Bausch & Lomb Incorporated, Bayer AG, CooperVision, Dompe farmaceutici S.p.A., Johnson & Johnson, Novartis AG, ReGenTree, LLC., and Walgreens.

Key questions answered in this report

  • Which strategic collaboration, merger and acquisitions are taking place in the neurotrophic keratitis market?

  • Which key players are manufacturing medicines for the treatment of neurotrophic keratitis market?

  • What is the disease etiology of neurotrophic keratitis and medicines prescribed as per the different stages of the disease?

  • What is Oxervate and how will it perform during the forecast period?

  • What will be the market performance of developing regions such as Asia Pacific and Latin America in the neurotrophic keratitis market?

Key Topics Covered:

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Treatment
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global NK Market Portraiture
2.2. Global NK Market, by Treatment, 2020 (US$ Mn)
2.3. Global NK Market, by Geography, 2020 (US$ Mn)

Chapter 3. Neurotrophic Keratitis (NK) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2020
3.6. Competitive Analysis: Global NK Market, by Key Players, 2020

Chapter 4. Global Neurotrophic Keratitis (NK) Market, by Treatment
4.1. Overview
4.2. Preservative Free Artificial Tears
4.3. Topical Antibiotics
4.4. Tarsorraphy
4.5. Amniotic Membrane Transplantation
4.6. Bandage Contact Lenses
4.7. Recombinant Human Nerve Growth Factor (Oxervate)
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. RGN-259

Chapter 5. Global Neurotrophic Keratitis (NK) Market, by Geography
5.1. Overview
5.2. North America NK Market Analysis, 2019 - 2029
5.2.1. North America NK Market, by Treatment, 2019 - 2029 (US$ Mn)
5.2.2. North America NK Market, by Country, 2019 - 2029 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe NK Market Analysis, 2019 - 2029
5.3.1. Europe NK Market, by Treatment, 2019 - 2029 (US$ Mn)
5.3.2. Europe NK Market, by Country/Region, 2019 - 2029 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific NK Market Analysis, 2019 - 2029
5.4.1. Asia Pacific NK Market, by Treatment, 2019 - 2029 (US$ Mn)
5.4.2. Asia Pacific NK Market, by Country/Region, 2019 - 2029 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America NK Market Analysis, 2019 - 2029
5.5.1. Latin America NK Market, by Treatment, 2019 - 2029 (US$ Mn)
5.5.2. Latin America NK Market, by Country/Region, 2019 - 2029 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa NK Market Analysis, 2019 - 2029
5.6.1. MEA NK Market, by Treatment, 2019 - 2029 (US$ Mn)
5.6.2. MEA NK Market, by Region, 2019 - 2029 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Abbott Laboratories, Inc.
6.3. Bausch & Lomb Incorporated
6.4. Bayer AG
6.5. CooperVision
6.6. Dompe farmaceutici S.p.A.
6.7. Johnson & Johnson
6.8. Novartis AG
6.9. ReGenTree, LLC.
6.10. Walgreens

For more information about this report visit https://www.researchandmarkets.com/r/a1i285

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900